

Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A₂ in endothelial cells via p42/p44 mitogen-activated protein kinase

Caroline Wheeler-Jones^{1,b}, Robin Abu-Ghazaleh^a, Rosario Cospedal^a, Rebecca A. Houliston^b, John Martin^a, Ian Zachary^{a,*}

^aCruciform Project and Department of Medicine, University College London, 5 University Street, London WC1E 6JJ, UK

^bVascular Biology Research Centre, King's College London, Campden Hill Road, Kensington, London W8 7AH, UK

Received 4 November 1997

Abstract Vascular endothelial growth factor (VEGF) stimulated a time- and concentration-dependent increase in PGI₂ synthesis in human umbilical vein endothelial cells with a mean maximum increase of 2-fold above basal levels at 25 ng/ml after 60 min. VEGF also rapidly stimulated the release of arachidonic acid and phosphorylation and activation of cytosolic phospholipase A₂ (cPLA₂). The VEGF-related factor, placenta growth factor (PIGF), had little effect on PGI₂ synthesis, arachidonic acid release or cPLA₂ activation. PD98059, a selective inhibitor of MAP kinase kinase, caused complete inhibition of VEGF-stimulated MAP kinase activity, PGI₂ synthesis and cPLA₂ gel retardation, but had no effect on VEGF-induced vWF secretion. These findings provide the first evidence that VEGF can stimulate PGI₂ synthesis via cPLA₂-mediated arachidonic acid release and indicate that VEGF stimulation of this biosynthetic pathway may occur, at least in part, via activation of p42/p44 MAP kinases.

© 1997 Federation of European Biochemical Societies.

Key words: Thrombin; Signal transduction; Endothelium; Arachidonic acid; Von Willebrand factor

1. Introduction

The endothelium of the arterial wall releases a variety of factors which play essential roles in the control of vascular tone and reactivity [1,2]. One of these factors, the prostanoid PGI₂, is an important regulator of vascular functions including vasodilatation, platelet aggregation, vascular permeability and vascular smooth muscle cell (VSMC) proliferation [3,4]. PGI₂ production is stimulated in cultured endothelial cells by a variety of agonists acting through receptors with seven transmembrane domains coupled to G-proteins, including thrombin, histamine, ATP and bradykinin [5–7]. In contrast

to the well-established effects of agonists for G-protein coupled receptors, there have been few reports of endothelial PGI₂ production in response either to cytokines or polypeptide growth factors for receptor protein tyrosine kinases.

A major pathway leading to PGI₂ synthesis results from agonist-induced activation of the cytosolic form of PLA₂ (cPLA₂), the release of arachidonic acid from membrane phospholipids and its conversion into PGI₂ via cyclooxygenase and PGI synthase [8–10]. Recent evidence shows that thrombin-stimulated activation of cPLA₂ and PGI₂ synthesis involves phosphorylation by members of the mitogen-activated protein (MAP) kinase family, including p42/p44 Erks [11–13] and p38 MAP kinase [14–16].

The 46 kDa secreted polypeptide factor, vascular endothelial growth factor (VEGF) plays an essential role in angiogenesis in vivo [17]. VEGF expression is upregulated by hypoxia and by cytokines and growth factors in arterial vascular smooth muscle cells (VSMC) [18,19] and recent findings suggest that VEGF may have a role in maintaining normal vascular function and inhibiting VSMC proliferation in vivo [20–25]. In particular, VEGF gene transfer inhibits intimal VSMC proliferation in models of arterial neo-intima formation [22–25] but the mechanism(s) involved in this effect are not clearly understood. The biological effects of VEGF are mediated by two protein tyrosine kinase receptors, the *fms*-like tyrosine kinase, Flt-1, and KDR/Flk-1 [26,27]. VEGF exhibits high-affinity binding to both receptors, and the closely related factor, placental growth factor (PIGF), is a specific ligand for Flt-1 and does not bind to KDR/Flk-1 [28].

In the present paper we show that VEGF induces PGI₂ generation via activation of cPLA₂. Further, we present evidence that PGI₂ production induced by VEGF is mediated by the MAP kinase pathway. These findings suggest one important mechanism by which vascular protective actions of this factor may be mediated.

2. Materials and methods

2.1. Cell culture

HUVECs were obtained from fresh umbilical cords by collagenase digestion and cultured on 1% gelatin-coated plates in medium 199 (M199) supplemented with 20% fetal calf serum and endothelial cell growth supplement [29]. Cells were used after 6–8 days or when the cells had formed a confluent monolayer.

2.2. PGI₂ assay

HUVECs were washed twice in serum-free M199 (pH 7.4) and after treatments the PGI₂ content of cell supernatants was quantified by radioimmunoassay of 6-keto PGF_{1α}, the stable breakdown product of PGI₂ as described [30].

*Corresponding author. Fax: +44 (171) 209 6212.
E-mail: I.Zachary@ucl.ac.uk

¹Present address: The Royal Veterinary College, University of London, Royal College Street, London NW1 0TU, UK.

Abbreviations: BSA, bovine serum albumin; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; HUVEC, human umbilical vein endothelial cells; IgG, immunoglobulin G; MAP kinase, mitogen-activated protein kinase; mAb, monoclonal antibody; PBS, phosphate-buffered saline; PGI₂, prostacyclin; cPLA₂, cytosolic phospholipase A₂; PIGF, placenta growth factor; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; VEGF, vascular endothelial growth factor; vWF, von Willebrand factor; VSMC, vascular smooth muscle cells

2.3. Arachidonic acid release

Arachidonic acid release was determined essentially as described [31]. Confluent HUVEC cultures were incubated for 24 h with [5,6,8,9,11,12,14,15-³H]arachidonic acid (1 mCi/ml, 211 Ci/mmol). The cells were then washed twice with M199 and incubated in 1 ml of this medium supplemented with 0.3% BSA (essential fatty acid free) and other additions as indicated. The medium was then removed, centrifuged at 16000×g for 5 min, and the radioactivity in the supernatant was determined by counting in a scintillation counter.

2.4. Western blotting procedures

Assays of MAP kinase activity and cPLA₂ activation were performed by Western blotting of whole cell extracts using, respectively, an antibody which specifically recognizes p42 and p44 MAP kinases (Erk-1 and Erk-2) activated by phosphorylation at Tyr204 [32] and a polyclonal antiserum to cPLA₂ [15,16]. Immunoreactive bands were visualized by chemiluminescence using HRP-conjugated anti-mouse or anti-rabbit IgG and ECL reagent.

2.5. Assay of vWF secretion

vWF secretion was measured by ELISA as described [30] in samples of medium obtained from confluent cultures of HUVECs which had been treated with factors, as indicated. Plates were coated with the anti-vWF mAb CLBRAg35, and the lower detection limit of the assay was approximately 1.0 mU/ml.

2.6. Materials

Recombinant VEGF was obtained from R&D Systems. Recombinant PIGF was the gift of Professor Werner Risau and was also obtained from R&D Systems. Polyclonal cPLA₂ antiserum was the gift of Dr. Ruth Kramer (Eli Lilly, Indianapolis, IN). The anti-vWF mAb CLBRAg35 was the gift of Dr. J.A. Van Mourik (Central Blood Laboratory, Amsterdam, The Netherlands). Antibody to the activated phosphorylated form of p42/p44 MAP kinase was purchased from New England Biolabs Inc. [5,6,8,9,11,12,14,15-³H]arachidonic acid, ECL reagents and HRP-conjugated anti-mouse IgG were from Amer-

sham, UK. Goat anti-rabbit HRP-conjugated IgG was from Pierce Inc. Other reagents used were of the purest grade available.

3. Results

Confluent cultures of HUVEC were treated for various times up to 2 h with VEGF and the medium was removed and assayed for 6-keto PGF_{1α}, a stable metabolic breakdown product of PGI₂. As shown in Fig. 1A VEGF caused a time-dependent increase in the production of PGI₂ which was detectable as early as 15 min after addition of the factor, continued to increase for up to 60 min, and was sustained for up to 2 h (Fig. 1A). VEGF stimulation of PGI₂ production was also concentration-dependent. After a 60 min incubation, an increase in PGI₂ synthesis was detectable at 5 ng/ml, was half-maximal at 10 ng/ml and reached a maximum at 15 ng/ml. It was consistently noted that VEGF-induced PGI₂ synthesis underwent a small decline at 25 ng/ml (Fig. 1B).

The effect of VEGF was weaker than that of thrombin, a potent inducer of PGI₂ synthesis and PIGF, a specific ligand for the Flt-1 receptor [28], induced a much weaker stimulation of PGI₂ synthesis compared to VEGF. The mean fold increases in 6-keto PGF_{1α} produced by 60 min incubations with 25 ng/ml VEGF, 60 ng/ml PIGF and 1 U/ml thrombin were, respectively, 2.0-, 1.3- and 4.4-fold above the mean control unstimulated level.

To examine the effect of VEGF on the mobilization of arachidonic acid, HUVECs were preincubated with radiolabelled arachidonic acid for 24 h and challenged with VEGF for different times. Arachidonic acid release experiments were




Fig. 1. VEGF-induced PGI₂ synthesis and arachidonic acid release in HUVEC. A and B: HUVECs were incubated in the absence (open circles) or presence (closed circles) of 25 ng/ml VEGF for the times indicated (A) or in the presence of different concentrations of VEGF for 60 min (B). 6-keto PGF_{1α} was assayed as described. The results shown are representative of three experiments. Values are presented as the mean ± S.E.M. of 3–4 determinations. C and D: Cells prelabelled with [³H]arachidonic acid were incubated for different times (C) with 1.0 U/ml thrombin (closed circles) or 25 ng/ml VEGF (closed triangles) or without addition. The concentration-dependence for VEGF (60 min incubation) is shown in D. The results shown are representative of three experiments and values are presented as the mean ± S.E.M. of triplicate determinations.

conducted in the presence of 0.3% BSA which binds avidly to the free fatty acid and acts as an extracellular ‘trap’ for arachidonic acid. As shown in Fig. 1C, VEGF caused an increase in label released into the medium of prelabelled cells which was evident at 10 min and reached a maximum at 30 min, after addition of the factor. As measured in parallel cultures, the time-course for VEGF-stimulated arachidonic acid release was very similar to that for thrombin (Fig. 1C). The concentration-dependence for VEGF-stimulated arachidonic acid release was very similar to that obtained for PGI₂ production, with a half-maximal effect at 2.5–5 ng/ml and a maximum at 10–20 ng/ml (Fig. 1D). Similar to the relative abilities of thrombin and VEGF to stimulate PGI₂ production, maximum VEGF-induced arachidonic acid release was consistently lower than that obtained for thrombin. In four experiments, VEGF and thrombin caused mean increases in the release of labelled arachidonic acid of 1.6- and 3.4-fold above the basal unstimulated level, respectively. PIGF caused no detectable increase in arachidonic acid release.

The conversion of cPLA₂ to its activated form can be monitored by a shift in its mobility in SDS-PAGE gels from a fast- to a slow-migrating form [15,16]. In Western blots of extracts of control HUVECs, antibody to cPLA₂ recognized two distinct bands of approximately equal intensity and migrating with approximate *M_r* 97 000 (Fig. 3). Though cPLA₂ has a predicted molecular weight of 85 kDa, this protein has previously been reported to migrate in SDS-PAGE as a 97 kDa band [15,16]. VEGF at 25 ng/ml caused a marked increase in the immunoreactivity of the slow-migrating form of cPLA₂ and a concomitant relative decrease in the faster-migrating form, which was detectable after 2 min, reached a maximum after 15 min, and was sustained for up to 60 min after VEGF addition (Fig. 2, upper panel). In five independent experi-




Fig. 2. Effect of VEGF treatment on mobility of cPLA₂ in SDS-PAGE. HUVECs were incubated in the presence of 25 ng/ml VEGF for the times indicated (upper) or in the presence of the indicated concentrations of VEGF for 60 min, or with 1.0 U/ml thrombin (T) for 20 min (centre). In other experiments (bottom) cells were pretreated as indicated for 30 min with 25 μM PD98059 and then incubated with 25 ng/ml VEGF for 15 min as indicated. Whole-cell lysates were Western blotted using an anti-cPLA₂ antiserum. The positions of molecular weight markers (*M_r* × 10⁻³) and of phosphorylated (cPLA₂-P) and faster-migrating (cPLA₂) forms of cPLA₂ are indicated. The results shown are representative of 2–3 experiments.




Fig. 3. Effects of PD98059 on PGI₂ synthesis and vWF secretion induced by VEGF and thrombin. HUVEC were pre-treated for 30 min with the indicated concentrations of PD98059 (A) or in the absence (-) or presence (+) of 25 μM PD98059 (B) and subsequently incubated as indicated with 25 ng/ml VEGF or 1.0 U/ml thrombin for 60 min. Assays for 6-keto PGF_{1α} content (A) or vWF content (B) were as described. The results shown are representative of three similar experiments. Data are given as mean ± S.E.M. of triplicate determinations.

ments, VEGF consistently caused a marked increase in the immunoreactivity of the slower-migrating form of cPLA₂. The VEGF-induced decrease in the electrophoretic mobility of cPLA₂ was also concentration-dependent with a noticeable increase in the slow-migrating form at 2.5 ng/ml and a maximum increase at 5–10 ng/ml, the highest concentration tested (Fig. 2, middle panel). Thrombin also caused a striking shift in the mobility of cPLA₂ from a faster- to a slower-migrating form and, similar to the results obtained for PGI₂ synthesis and arachidonic acid release, the effect of thrombin was greater than that of VEGF with virtually complete disappearance of the faster-migrating form of the enzyme (Fig. 2, middle panel). PIGF caused no detectable shift in the mobility of immunoreactive cPLA₂ from faster to slower-migrating forms (results not shown).

It was next investigated whether VEGF-induced PGI₂ synthesis and cPLA₂ activation were mediated via activation of p42/p44 MAP kinases. We have previously reported that VEGF induces MAP kinase activation in HUVECs [29]. VEGF induced a detectable increase in activity of p42/p44 MAP kinases in confluent HUVEC at a concentration as low as 0.5 ng/ml, a half-maximal increase between 1 and 5 ng/ml, and a maximum effect at 10 ng/ml (results not shown). PIGF in the concentration range 1–60 ng/ml caused no significant increase in MAP kinase activity in HUVEC (results

not shown). In accord with our previous findings [29], VEGF stimulation of p42/p44 MAP kinases was completely inhibited by a 30 min pretreatment with 10 μ M PD98059, a selective inhibitor of MAP kinase kinase [33], the dual-specificity threonine and tyrosine kinase which specifically phosphorylates and activates p42/p44 MAP kinases. As shown in Fig. 2, pretreatment with PD98059 at 25 μ M completely blocked the VEGF-stimulated increase in the slow-migrating form of cPLA₂. It was noted that the inhibitor not only reversed the VEGF-dependent decrease in cPLA₂ gel mobility, but also decreased the immunoreactivity of the slower-migrating form below, and increased that of the faster-migrating form above control levels.

Pretreatment of HUVEC with 30 μ M PD98059 for 30 min completely inhibited PGI₂ production induced by a subsequent 60 min incubation with either 25 ng/ml VEGF or 1 U/ml thrombin (Fig. 3A). The effect of PD98059 on VEGF-induced PGI₂ synthesis was concentration-dependent with a half-maximal effect at approximately 5 μ M and a maximum inhibitory effect on stimulated PGI₂ production at 10 μ M (Fig. 3A). This correlated closely with the concentration-dependence for the effect of the inhibitor on VEGF-stimulated MAP kinase activity (results not shown). It was also noted that PD98059 reduced PGI₂ production in VEGF-treated cells to below the values measured in control cells, though this effect was only apparent at concentrations of the inhibitor greater than 10 μ M (Fig. 3A). VEGF induced a striking increase in vWF secretion (Fig. 3B) which was concentration- and time-dependent (results not shown). In contrast to its effect on cPLA₂ activation and PGI₂ synthesis, pretreatment of HUVECs with the inhibitor at 25 μ M had no effect on vWF secretion caused by a subsequent addition of either VEGF or thrombin (Fig. 3B).

4. Discussion

The results presented here show that VEGF stimulates a striking time- and concentration-dependent increase in PGI₂ production in HUVEC. We also show for the first time that VEGF stimulates the rapid mobilization of arachidonic acid from human endothelial cells and, as judged by a gel retardation assay, the rapid activation of cPLA₂. The concentration-dependencies for VEGF-induced PGI₂ production, arachidonic acid release and cPLA₂ activation were similar to each other (all within the range 5–10 ng/ml) and are also similar to the concentration-dependence reported for the effects of VEGF on mitogenesis, chemotaxis and other early signalling events in HUVECs [29,34]. These results indicate that VEGF stimulation of arachidonic acid release and PGI₂ synthesis are mediated through high-affinity receptors for this factor in HUVECs. Since PlGF induced PGI₂ synthesis more weakly than VEGF and also failed to significantly increase either arachidonic acid release or cPLA₂ mobility shift, these results are most consistent with the conclusion that stimulation of PGI₂ production by VEGF in HUVECs is mediated primarily by KDR/Flk-1 receptors.

Recent findings have implicated the p42/p44 MAP kinases in the phosphorylation and activation of cPLA₂. The finding that VEGF causes a rapid shift in the electrophoretic mobility of cPLA₂ is most consistent with increased phosphorylation, and hence activation, of the enzyme. This inference is supported by the finding that thrombin, which is known to stim-

ulate cPLA₂ phosphorylation and activation in platelets [15,16], caused a similar shift in cPLA₂ mobility in HUVECs. The results presented here also show that VEGF activates p42/p44 MAP kinases and that inhibition of this pathway with a selective inhibitor of MAP kinase kinase, PD98059, blocks PGI₂ production and the increased gel retardation of cPLA₂ induced by VEGF. PD98059 was previously reported to block thrombin-induced PGI₂ production in HUVECs [13]. Though it is impossible to preclude non-specific effects of the inhibitor, the effect of PD98059 was at least partially selective since it had no effect on vWF secretion stimulated either by VEGF or by thrombin. Furthermore, the inhibitory effect of PD98059 on PGI₂ synthesis could be reversed by addition of exogenous arachidonic acid to the cells (results not shown).

Compared to the effect of the potent inducer of p38 kinase activator, anisomycin, VEGF did not significantly increase p38 kinase activity in HUVECs (results not shown) suggesting that p38 kinase is unlikely to play a major role in VEGF-induced cPLA₂ activation. It is plausible that other signalling mechanisms may contribute to VEGF stimulation of PGI₂ synthesis and arachidonic acid release, including elevation of intracellular Ca²⁺. cPLA₂ is sensitive to physiological Ca²⁺ concentrations [8] and VEGF is able to induce the mobilization of Ca²⁺ from intracellular stores [26,27,35]. Since the Ca²⁺ ionophore ionomycin can stimulate PGI₂ synthesis in HUVECs without activating the MAP kinase pathway (C.J.W. Wheeler-Jones et al., unpublished results), any Ca²⁺-dependent effect of VEGF is likely to occur independently of the MAP kinase-dependent pathway. The finding that a MAP kinase kinase inhibitor blocks VEGF-stimulated PGI₂ synthesis but does not affect vWF secretion suggests that these two biological responses to VEGF are triggered by distinct intracellular signalling pathways. The precise relationship between Ca²⁺ fluxes, MAP kinase activation and PGI₂ synthesis in the action of VEGF requires more detailed delineation.

The mechanisms involved in VEGF-dependent inhibition of intimal VSMC hyperplasia are unclear but have been proposed to be primarily due to the stimulation of endothelial re-growth. Given that prostanoid-stimulated elevation of intracellular cyclic AMP is a potent inhibitor of VSMC mitogenesis [2], it is attractive to hypothesize that VEGF stimulation of PGI₂ has other biological effects in the vascular system, including vasodilatation, increased vascular permeability and the inhibition of platelet aggregation [4–6], and it is entirely possible that VEGF-induced PGI₂ production may have implications for the regulation of other aspects of vascular reactivity. For example, the reported effects of VEGF on vasodilatation of blood vessels [21,22] may be mediated in part by PGI₂.

The finding that VEGF stimulates PGI₂ production, arachidonic acid mobilization and cPLA₂ activation probably through a MAP kinase-dependent pathway identifies both a novel function and a new mechanism of action for VEGF in endothelial cells. Activation of this pathway by VEGF is consistent with a role for this factor in the protection of the intact vessel wall. The ability of VEGF both to augment endothelial cell responses and to promote endothelial regeneration makes this factor ideally suited for a role in the maintenance and renewal of normal blood vessel functions.

Acknowledgements: This work was supported by the British Heart Foundation and by European Community Biomed II Grant

PL950329. C.W.-J., R.C. and I.Z. are supported by the British Heart Foundation. J.M. is BHF Professor of Cardiovascular Science.

References

- [1] Hudlicka, O., Brown, M. and Egginton, S. (1992) *Physiol. Rev.* 72, 369–417.
- [2] Ross, R. (1993) *Nature* 362, 801–809.
- [3] Moncada, S. (1982) *Br. J. Pharmacol.* 76, 3–31.
- [4] Luscher, T.F. and Noll, G. in: *The Endothelium in Cardiovascular Disease* (Luscher, T.F., Ed.), pp. 1–24, Springer-Verlag, Berlin.
- [5] Jaffe, E.A., Grulich, J., Weksler, B., Hampel, G. and Watanabe, K. (1987) *J. Biol. Chem.* 262, 8557–8565.
- [6] Baenziger, N.L., Fogerty, F.J., Mertz, L.F. and Chernuta, L.F. (1981) *Cell* 24, 915–923.
- [7] Carter, T.D., Newton, J.S., Jacob, R. and Pearson, J.D. (1990) *Biochem. J.* 272, 217–221.
- [8] Leslie, C.C. (1997) *J. Biol. Chem.* 272, 16709–16712.
- [9] Lin, L.-L., Lin, A.Y. and Knopf, J.L. (1992) *Proc. Natl. Acad. Sci. USA* 89, 6147–6151.
- [10] Clark, J.D., Lin, L.-L., Kriz, R.W., Ramesha, C.S., Sultzman, L.A., Lin, A.Y., Milona, N. and Knopf, J.L. (1991) *Cell* 65, 1043–1051.
- [11] Lin, L.L., Wartmann, M., Lin, A.Y., Knopf, J.L., Seth, A. and Davis, R.J. (1993) *Cell* 72, 269–278.
- [12] Nemenoff, R.A., Winitz, S., Qian, N.X., Putten, V.V., Johnson, G.L. and Heasley, L.E. (1993) *J. Biol. Chem.* 268, 1960–1964.
- [13] Wheeler-Jones, C.P.D., May, M.J., Houliston, R.A. and Pearson, J.D. (1996) *FEBS Lett.* 388, 180–184.
- [14] Winitz, S., Gupta, S.K., Qian, N.X., Heasley, L.E., Nemenoff, R.A. and Johnson, G.L. (1994) *J. Biol. Chem.* 269, 1889–1895.
- [15] BorshHaubold, A.G., Kramer, R.M. and Watson, S.P. (1995) *J. Biol. Chem.* 270, 25885–25892.
- [16] Kramer, R.M., Roberts, E.F., Um, S.L., BorshHaubold, A.G., Watson, S.P., Fisher, M.J. and Jakubowski, J.A. (1996) *J. Biol. Chem.* 271, 27723–27729.
- [17] Risau, W. (1997) *Nature* 386, 671–674.
- [18] Stavri, G., Hong, Y., Zachary, I., Breier, G., Baskerville, P., Hla-Herttualla, S., Risau, W., Martin, J. and Erusalimsky, J. (1995) *FEBS Lett.* 358, 311–315.
- [19] Stavri, G., Zachary, I., Baskerville, P., Martin, J. and Erusalimsky, J. (1995) *Circulation* 92, 5–8.
- [20] Alon, T., Hemo, I., Itin, A., Pe'er, J., Stone, J. and Keshet, E. (1995) *Nature Med.* 1, 1024–1028.
- [21] Ku, D.D., Zaleski, J.K., Liu, S. and Brock, T.A. (1993) *Am. J. Physiol.* 265, H586–H592.
- [22] van der Zee, R., Murohara, T., Luo, Z., Zollman, F., Passeri, J., Lekutat, C. and Isner, J.M. (1997) *Circulation* 95, 1030–1037.
- [23] Asahara, T., Bauters, C., Pastore, C., Kearney, M., Rossow, S., Bunting, S., Ferrara, N., Symes, J.F. and Isner, J.M. (1995) *Circulation* 91, 2793–2801.
- [24] Asahara, T., Chen, D., Tsurumi, Y., Kearney, M., Rossow, S., Passeri, J., Symes, J.F. and Isner, J.M. (1996) *Circulation* 94, 3291–3302.
- [25] Laitinen, M., Zachary, I., Breier, G., Pakkanen, T., Hakkinen, T., Luoma, J., Abedi, H., Risau, W., Soma, M., Laakso, M., Martin, J.F. and Yla-Herttualla, S. (1997) *Human Gene Ther.* 8, 1737–1744.
- [26] de Vries, C., Escobedo, J.A., Ueno, H., Houck, K., Ferrara, N. and Williams, L.T. (1992) *Science* 255, 989–991.
- [27] Quinn, T.P., Peters, K.G., De Vries, C., Ferrara, N. and Williams, L.T. (1993) *Proc. Natl. Acad. Sci. USA* 90, 7533–7537.
- [28] Clauss, M., Weich, H., Breier, G., Knies, U., Rockl, W., Waltenberger, J. and Risau, W. (1996) *J. Biol. Chem.* 271, 17629–17634.
- [29] Abedi, H. and Zachary, I. (1997) *J. Biol. Chem.* 272, 15442–15451.
- [30] Wheeler-Jones, C.P.D., May, J.J., Morgan, A.J., Jacob, R. and Pearson, J.D. (1996) *Biochem. J.* 315, 407–416.
- [31] Domin, J. and Rozengurt, E. (1993) *J. Biol. Chem.* 268, 8927–8934.
- [32] Payne, D.M., Rossomondo, A.J., Martino, P., Erickson, A.K., Her, J.H., Shabanowitz, J., Hunt, D.F., Weber, M.J. and Sturgill, T.W. (1991) *EMBO J.* 10, 885–892.
- [33] Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. and Saltiel, A.R. (1995) *Proc. Natl. Acad. Sci. USA* 92, 7686–7689.
- [34] Waltenberger, J., Claesson-Welsh, L., Siegbahn, A., Shibuya, M. and Heldin, C.-H. (1994) *J. Biol. Chem.* 269, 26988–26995.
- [35] Brock, T.A., Dvorak, H.F. and Senger, D.R. (1991) *Am. J. Pathol.* 138, 213–221.